FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294908082> ?p ?o ?g. }

• W4294908082 endingPage "893" @default.
• W4294908082 startingPage "882" @default.
• W4294908082 abstract "Whether improved glucose control with hybrid closed-loop therapy can preserve C-peptide secretion as compared with standard insulin therapy in persons with new-onset type 1 diabetes is unclear.In a multicenter, open-label, parallel-group, randomized trial, we assigned youths 10.0 to 16.9 years of age within 21 days after a diagnosis of type 1 diabetes to receive hybrid closed-loop therapy or standard insulin therapy (control) for 24 months. The primary end point was the area under the curve (AUC) for the plasma C-peptide level (after a mixed-meal tolerance test) at 12 months after diagnosis. The analysis was performed on an intention-to-treat basis.A total of 97 participants (mean [±SD] age, 12±2 years) underwent randomization: 51 were assigned to receive closed-loop therapy and 46 to receive control therapy. The AUC for the C-peptide level at 12 months (primary end point) did not differ significantly between the two groups (geometric mean, 0.35 pmol per milliliter [interquartile range, 0.16 to 0.49] with closed-loop therapy and 0.46 pmol per milliliter [interquartile range, 0.22 to 0.69] with control therapy; mean adjusted difference, -0.06 pmol per milliliter [95% confidence interval {CI}, -0.14 to 0.03]). There was not a substantial between-group difference in the AUC for the C-peptide level at 24 months (geometric mean, 0.18 pmol per milliliter [interquartile range, 0.06 to 0.22] with closed-loop therapy and 0.24 pmol per milliliter [interquartile range, 0.05 to 0.30] with control therapy; mean adjusted difference, -0.04 pmol per milliliter [95% CI, -0.14 to 0.06]). The arithmetic mean glycated hemoglobin level was lower in the closed-loop group than in the control group by 4 mmol per mole (0.4 percentage points; 95% CI, 0 to 8 mmol per mole [0.0 to 0.7 percentage points]) at 12 months and by 11 mmol per mole (1.0 percentage points; 95% CI, 7 to 15 mmol per mole [0.5 to 1.5 percentage points]) at 24 months. Five cases of severe hypoglycemia occurred in the closed-loop group (in 3 participants), and one occurred in the control group; one case of diabetic ketoacidosis occurred in the closed-loop group.In youths with new-onset type 1 diabetes, intensive glucose control for 24 months did not appear to prevent the decline in residual C-peptide secretion. (Funded by the National Institute for Health and Care Research and others; CLOuD ClinicalTrials.gov number, NCT02871089.)." @default.
• W4294908082 created "2022-09-07" @default.
• W4294908082 creator A5005971350 @default.
• W4294908082 creator A5012170772 @default.
• W4294908082 creator A5013626494 @default.
• W4294908082 creator A5018911748 @default.
• W4294908082 creator A5023259818 @default.
• W4294908082 creator A5030566919 @default.
• W4294908082 creator A5032123532 @default.
• W4294908082 creator A5033841981 @default.
• W4294908082 creator A5040327007 @default.
• W4294908082 creator A5046837679 @default.
• W4294908082 creator A5048565116 @default.
• W4294908082 creator A5054333092 @default.
• W4294908082 creator A5059687616 @default.
• W4294908082 creator A5061789378 @default.
• W4294908082 creator A5063960889 @default.
• W4294908082 creator A5074796821 @default.
• W4294908082 creator A5086879303 @default.
• W4294908082 date "2022-09-08" @default.
• W4294908082 modified "2023-10-18" @default.
• W4294908082 title "Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes" @default.
• W4294908082 cites W1988519907 @default.
• W4294908082 cites W2028990915 @default.
• W4294908082 cites W2087759407 @default.
• W4294908082 cites W2119813462 @default.
• W4294908082 cites W2147072756 @default.
• W4294908082 cites W2148495167 @default.
• W4294908082 cites W2294577436 @default.
• W4294908082 cites W2341744959 @default.
• W4294908082 cites W2807893746 @default.
• W4294908082 cites W2890424595 @default.
• W4294908082 cites W2946228794 @default.
• W4294908082 cites W2981310284 @default.
• W4294908082 cites W3012313076 @default.
• W4294908082 cites W3080244655 @default.
• W4294908082 cites W3118986275 @default.
• W4294908082 cites W3185481711 @default.
• W4294908082 cites W3186618984 @default.
• W4294908082 cites W3187495758 @default.
• W4294908082 cites W4235093819 @default.
• W4294908082 doi "https://doi.org/10.1056/nejmoa2203496" @default.
• W4294908082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36069870" @default.
• W4294908082 hasPublicationYear "2022" @default.
• W4294908082 type Work @default.
• W4294908082 citedByCount "21" @default.
• W4294908082 countsByYear W42949080822022 @default.
• W4294908082 countsByYear W42949080822023 @default.
• W4294908082 crossrefType "journal-article" @default.
• W4294908082 hasAuthorship W4294908082A5005971350 @default.
• W4294908082 hasAuthorship W4294908082A5012170772 @default.
• W4294908082 hasAuthorship W4294908082A5013626494 @default.
• W4294908082 hasAuthorship W4294908082A5018911748 @default.
• W4294908082 hasAuthorship W4294908082A5023259818 @default.
• W4294908082 hasAuthorship W4294908082A5030566919 @default.
• W4294908082 hasAuthorship W4294908082A5032123532 @default.
• W4294908082 hasAuthorship W4294908082A5033841981 @default.
• W4294908082 hasAuthorship W4294908082A5040327007 @default.
• W4294908082 hasAuthorship W4294908082A5046837679 @default.
• W4294908082 hasAuthorship W4294908082A5048565116 @default.
• W4294908082 hasAuthorship W4294908082A5054333092 @default.
• W4294908082 hasAuthorship W4294908082A5059687616 @default.
• W4294908082 hasAuthorship W4294908082A5061789378 @default.
• W4294908082 hasAuthorship W4294908082A5063960889 @default.
• W4294908082 hasAuthorship W4294908082A5074796821 @default.
• W4294908082 hasAuthorship W4294908082A5086879303 @default.
• W4294908082 hasBestOaLocation W42949080821 @default.
• W4294908082 hasConcept C119060515 @default.
• W4294908082 hasConcept C126322002 @default.
• W4294908082 hasConcept C134018914 @default.
• W4294908082 hasConcept C141071460 @default.
• W4294908082 hasConcept C168563851 @default.
• W4294908082 hasConcept C176674119 @default.
• W4294908082 hasConcept C203092338 @default.
• W4294908082 hasConcept C204243189 @default.
• W4294908082 hasConcept C2777180221 @default.
• W4294908082 hasConcept C2781232474 @default.
• W4294908082 hasConcept C44249647 @default.
• W4294908082 hasConcept C555293320 @default.
• W4294908082 hasConcept C71924100 @default.
• W4294908082 hasConceptScore W4294908082C119060515 @default.
• W4294908082 hasConceptScore W4294908082C126322002 @default.
• W4294908082 hasConceptScore W4294908082C134018914 @default.
• W4294908082 hasConceptScore W4294908082C141071460 @default.
• W4294908082 hasConceptScore W4294908082C168563851 @default.
• W4294908082 hasConceptScore W4294908082C176674119 @default.
• W4294908082 hasConceptScore W4294908082C203092338 @default.
• W4294908082 hasConceptScore W4294908082C204243189 @default.
• W4294908082 hasConceptScore W4294908082C2777180221 @default.
• W4294908082 hasConceptScore W4294908082C2781232474 @default.
• W4294908082 hasConceptScore W4294908082C44249647 @default.
• W4294908082 hasConceptScore W4294908082C555293320 @default.
• W4294908082 hasConceptScore W4294908082C71924100 @default.
• W4294908082 hasFunder F4320309446 @default.
• W4294908082 hasFunder F4320310820 @default.
• W4294908082 hasFunder F4320332161 @default.
• W4294908082 hasIssue "10" @default.
• W4294908082 hasLocation W42949080821 @default.

• next